Patents Assigned to AstraZeneca
  • Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
    Publication number: 20100069408
    Abstract: The invention provides new triazolo[4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation.
    Type: Application
    Filed: November 18, 2009
    Publication date: March 18, 2010
    Applicant: AstraZeneca AB
    Inventors: David Hardern, Anthony Ingall, Brian Springthorpe, Paul Willis, Simon Guile
  • PHOSPHONOXY QUINAZOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE
    Publication number: 20100069412
    Abstract: Quinazoline derivatives of formula (I): wherein A is 5-membered heteroaryl containing a nitrogen atom and one or two further nitrogen atoms; compositions containing them, processes for their preparation and their use in therapy.
    Type: Application
    Filed: April 28, 2009
    Publication date: March 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Nicola Murdoch Heron, Andrew Austen Mortlock, Frederic Henri JUNG, Georges Rene PASQUET
  • Inhaler Device Counter
    Publication number: 20100065649
    Abstract: Inhaler counter (20) comprising a counter housing (390), a rocker arm (200) with a pawl (210), the rocker arm being pivotally supported by the housing and arranged to perform a rocker movement in response to a linear actuation motion, a return spring (220) for resetting the rocker arm, a ratchet wheel (230) engagable with the pawl to convert the movement of the rocker arm into an incremental rotational motion of an axle arrangement (240) advancing a display means (60), the axle arrangement further comprising a back rotation prevention means (280) in the form of a spring loaded friction brake and a worm gear, the display means comprising rotatable indicator means (120) with teeth that engage the worm-gear and a stationary scale.
    Type: Application
    Filed: September 8, 2009
    Publication date: March 18, 2010
    Applicant: AstraZeneca AB
    Inventors: Nic Bowman, Douglas Bradshaw, Lennart Sõrby
  • MGluR5 modulators I
    Patent number: 7678796
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: March 16, 2010
    Assignee: AstraZeneca AB
    Inventors: Andreas Wallberg, Karolina Nilsson, Björn Holm, Mats Nagard, Kenneth Granberg, Abdelmalik Slassi, Louise Edwards, Methvin Isaac, Tao Xin, Tomislav Stefanac
  • Antibodies
    Publication number: 20100061993
    Abstract: A human antibody fragment, which antibody or fragment: (i) binds to a polypeptide having the amino acid sequence shown in SEQ ID NO: 1 of the C-terminal domain of Apolipoprotein E (ApoE-CTD) or the amino acid sequence of a part thereof; and (ii) binds to human plaques.
    Type: Application
    Filed: September 8, 2009
    Publication date: March 11, 2010
    Applicants: ASTRAZENECA AB, DYAX CORPORATION
    Inventors: Christer Nordstedt, Tom Goldschmidt, Maria Henderikx, René Hoet, Henricus Hoogenboom, Simon Hufton, Christin V. Andersson, Johanna Lindquist, Dan Sunnemark, Sergy Leonov
  • Method for Delivering A Pharmaceutical Composition to Patient in Need Thereof
    Publication number: 20100062064
    Abstract: The present disclosure is directed to a method for delivering a pharmaceutical composition to a patient in need thereof, comprising: administering to said patient a pharmaceutical composition in unit dose form comprising naproxen, or pharmaceutically acceptable salt thereof, and esomeprazole, or pharmaceutically acceptable salt thereof
    Type: Application
    Filed: September 3, 2009
    Publication date: March 11, 2010
    Applicants: ASTRAZENECA UK LTD., POZEN INC.
    Inventors: Brian Ault, Mark Sostek, Everardus Orlemans, John R. Plachetka
  • Alkyl urea substituted pyridines
    Patent number: 7674801
    Abstract: Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.
    Type: Grant
    Filed: December 4, 2007
    Date of Patent: March 9, 2010
    Assignee: AstraZeneca AB
    Inventors: Gregory Steven Basarab, Shanta Bist, John Irvin Manchester, Brian Sherer
  • AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES
    Publication number: 20100056508
    Abstract: The present invention provides compounds of formula (I), wherein k, Ar, R2, R3, R4, R5, R4?, R5?, R6, R7, A, D, m and E are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: December 19, 2007
    Publication date: March 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Lilian Alcaraz, Roger Victor Bonnert, Stephen Connolly, Anthony Ronald Cook, Adrian Fisher, Alexander Humphries, Piotr Raubo
  • COMPOUNDS AND USES THEREOF - 152
    Publication number: 20100056492
    Abstract: This invention relates to novel compounds having the structural Formula (I) below: and their pharmaceutically acceptable salts or tautomers, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of at least one symptom or condition associated with schizophrenia and other psychotic disorders, dementia and other cognitive disorders, anxiety disorders, mood disorders, sleep disorders, disorders usually first diagnosed in infancy, childhood, or adolescence and neurodegenerative disorders.
    Type: Application
    Filed: December 19, 2007
    Publication date: March 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Peter Bernstein, James B. Campbell
  • Compounds Suitable As Precursors to Compounds that are Useful for Imaging Amyloid Deposits
    Publication number: 20100056796
    Abstract: The present invention relates to novel derivatives that are suitable as precursors to compounds that are useful for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. The compounds deriving from these precursors are useful in methods of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease by positron emission tomography (PET) as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents. Furthermore, the present invention also discloses the precursor compounds in crystalline form.
    Type: Application
    Filed: August 20, 2009
    Publication date: March 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Seth Bjõrk, Peter Johnstrõm, Nils Anders Nilsson, Katinka Ruda, Per Magnus Schou, Britt-Marie Swahn, Vern Delisser
  • Pharmaceutical composition containing an active ingredient and a micronised carrier/diluent
    Patent number: 7670625
    Abstract: The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: March 2, 2010
    Assignee: AstraZeneca AB
    Inventor: Eva Trofast
  • Heteroaryl benzamide derivatives
    Patent number: 7671060
    Abstract: The invention relates to a novel group of compounds of Formula (I) or a salt thereof: wherein R1, R2, R3, n, A and HET-1 are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK) such as type 2 diabetes. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by GLK using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: October 26, 2007
    Date of Patent: March 2, 2010
    Assignee: AstraZeneca AB
    Inventors: Nathaniel George Martin, Darren McKerrecher, Kurt Gordon Pike, Michael James Waring
  • Heteroaryl substituted benzoxazoles
    Patent number: 7670591
    Abstract: The present invention relates to novel heteroaryl substituted benzoxazole derivatives and therapeutic uses for such compounds, having the structural formula (Ia) below: and to their pharmaceutically acceptable salt, compositions and methods of use. Furthermore, the invention relates to novel heteroaryl substituted benzoxazole derivatives that are suitable for imaging amyloid deposits in living patients, their compositions, methods of use and processes to make such compounds. More specifically, the present invention relates to a method of imaging amyloid deposits in brain in vivo to allow antemortem diagnosis of Alzheimer's disease as well as measuring clinical efficacy of Alzheimer's disease therapeutic agents.
    Type: Grant
    Filed: June 14, 2007
    Date of Patent: March 2, 2010
    Assignee: AstraZeneca AB
    Inventors: Jonas Malmstrom, David Pyring, Can Slivo, Daniel Sohn, Britt-Marie Swahn, David Wensbo
  • Process for preparing dibenzothiazepine compounds
    Patent number: 7671195
    Abstract: A dibenzothiazepine compound is suitably prepared by subjecting a 2-amino-2?-carboxy-diphenylsulfide compound to dehydration-condensation reaction in the presence of an acidic catalyst; the 2-amino-2?-carboxy-diphenylsulfide compound is suitably prepared by reducing a 2-nitro-2?-carboxy-diphenylsulfide compound in a lower aliphatic ester solvent; and the 2-nitro-2?-carboxy-diphenylsulfide compound is suitably prepared by reacting a nitrobenzene compound with a thiosalicylic acid compound in a mixture of a lower aliphatic alcohol and water.
    Type: Grant
    Filed: February 21, 2007
    Date of Patent: March 2, 2010
    Assignees: AstraZeneca UK Limited, UBE Industries, Ltd.
    Inventors: Paul Michael Murray, Luis-Manuel Vaz, Debra Ainge, Katsumasa Harada, Shigeyoshi Nishino, Kiyotaka Yoshii
  • New 2-Azetidinone Derivatives As Cholesterol Absorption Inhibitors For The Treatment Of Hyperlipidaemic Conditions
    Publication number: 20100048530
    Abstract: The invention relates to 2-azetidinone derivatives of formula (I), including pharmaceutically acceptable salts, solvates and prodrugs thereof. The compounds inhibit cholesterol absorption and are useful in the treatment of hyperlipidaemic conditions. The invention also relates to processes for their manufacture and to pharmaceutical compositions containing them.
    Type: Application
    Filed: June 21, 2006
    Publication date: February 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Mikael Dahlstrom, Staffan Karlsson, Peter Nordberg, Tore Skjaret, Ingemar Starke
  • New 2-Azetidinone Derivatives Useful In The Treatment Of Hyperlipidaemic Conditions
    Publication number: 20100048529
    Abstract: The invention relates to compounds of formula (I) and pharmaceutically acceptable salts, solvates, and prodrugs thereof, and to their use as cholesterol absorption inhibitors for the treatment of hyperlipidaemia. The invention also relates to processes for their manufacture and pharmaceutical compositions containing them.
    Type: Application
    Filed: June 21, 2006
    Publication date: February 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Mikael Dahlstrom, Staffan Karlsson, Malin Lemurell, Peter Nordberg, Ingemar Starke
  • PYRIMIDINE COMPOUNDS HAVING TIES (TEK) INHIBITORY ACTIVITY
    Publication number: 20100048543
    Abstract: The invention relates to a compound of the Formula I or salt thereof wherein Rx, Ry, Rz, R5, R6, A, B, L, n and m are as defined in the description. The invention also relates to pharmaceutical compositions of said compounds, the use of said compounds as medicaments and in the production of an anti-angiogenic effect in a warm-blooded animal. The invention also relates to processes for the preparation of said compounds.
    Type: Application
    Filed: January 27, 2006
    Publication date: February 25, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Clifford David Jones, Richard Williams Arthur Luke, William McCoull
  • Metalloproteinase inhibitors
    Patent number: 7666892
    Abstract: Compounds of the formula (I) wherein Z is SO2(N6) or N(R7)SO2 or N(R7)SO2N(R6) useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
    Type: Grant
    Filed: May 5, 2008
    Date of Patent: February 23, 2010
    Assignee: AstraZeneca AB
    Inventors: Anders Eriksson, Matti Lepistö, Michael Lundkvist, Magnus Munck Af Rosenschöld, Pavol Zlatoidsky
  • Process For The Production Of (Alkoxycarbonylamino)alkyl Sulfonates
    Publication number: 20100041911
    Abstract: There is provided a process for the preparation of a compound of formula I, which process comprises: (a) reaction of a compound of formula II, HO-D-NH2 II with a compound of formula III, followed by (b) reaction of the intermediate of formula IV thereby formed, IV with base and a compound of formula V, R2S(O)2L2 V, wherein the intermediate of formula IV is not isolated, and wherein D, R1, R2, L1 and L2 have meanings given in the description.
    Type: Application
    Filed: June 12, 2006
    Publication date: February 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: David Cladingboel, Adam Herring, Rhona Sinclair
  • Process for the Preparation of Substituted 2-Acetylamino-Alkoxyphenyl
    Publication number: 20100041905
    Abstract: The present invention relates to a novel process for the preparation of compounds of formula (V) wherein X, Q, R1, R1a and R2 are as defined in the specification, the compounds being useful in the preparation of therapeutic agents.
    Type: Application
    Filed: July 17, 2007
    Publication date: February 18, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Debra Ainge, Philip Cornwall, Duncan Michael Gill, Luis Manuel Vaz